HomeQuestion

Would you consider therapy with AI plus CDK4/6i or AI alone in a patient with oligometastatic HR+ breast cancer with complete response to initial chemotherapy?

2

Join the Discussion

Discuss the cases and questions guidelines don't cover.

Related Questions

In a patient with metastatic PIK3CA-mutant, HR-positive, HER2-low breast cancer who is intolerant to capivasertib, would you preferentially use another PIK3 inhibitor or switch to T-DXd?

What adjuvant therapy would you offer a postmenopausal woman with a new pT2N0 HR+/HER2+ breast cancer primary who is concurrently being treated with anastrozole/ribociclib for well controlled oligometastatic HR+/HER2- disease?

What are your top takeaways in Radiation Oncology from SABCS 2025?

What are the recommended second-line treatment options for patients with metastatic HER2+ breast cancer who have received frontline trastuzumab deruxtecan (T-DXd)?

How do you approach second-line therapy for patients with PD-L1 positive metastatic TNBC, after progression on sacituzumab govitecan + pembrolizumab?

Evidence Meets Expertise

For Physicians

Mednet AI
Community

Company

About
Careers
Publications
Blog

Support

FAQs
Code of Conduct
AI Community Guidelines
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.